Brief: SSY Group Obtains China Drug Production And Registration Approvals For Four Products
23/07/2026 12:22
BRIEF-SSY Group Obtains China Drug Production And Registration Approvals For Four Products July 23 (Reuters) - SSY Group Ltd 2005.HK:
OBTAINS CHINA DRUG PRODUCTION AND REGISTRATION APPROVALS FOR FOUR PRODUCTS
APPROVAL FOR HEMOFILTRATION REPLACEMENT FLUID OF SODIUM CITRATE (5000ML) FOR CRRT
APPROVAL FOR BENIDIPINE HYDROCHLORIDE TABLETS (4MG) FOR HYPERTENSION AND ANGINA, OTHERS
APPROVAL FOR POLYVINYL ALCOHOL EYE DROPS 1.4% (0.4ML: 5.6MG) FOR DRY EYES
APPROVAL FOR FAT EMULSION, AMINO ACIDS (17) AND GLUCOSE (19%) INJECTION (1540ML, 1026ML)
Further company coverage: 2005.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SSY
See all newsBrief: SSY Group Receives NMPA China Approval For Sodium Cromoglicate Eye Drops 2%
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth